The 4R-tauopathies represent a group of neurodegenerative disorders characterized by the preferential accumulation of four-repeat (4R) tau isoforms. While Progressive Supranuclear Palsy (PSP, Corticobasal Degeneration (CBD, Argyrophilic Grain Disease (AGD, Globular Glial Tauopathy (GGT, and FTDP-17 share common pathological features centred on tau dysfunction, each disease presents unique therapeutic opportunities and challenges. This page provides a comprehensive comparison of therapeutic targets across these conditions, highlighting both shared pathways and disease-specific approaches.
| Disease | Abbreviation | Key Pathological Feature | Primary Clinical Phenotype |
|---|---|---|---|
| Progressive Supranuclear Palsy | PSP | Neurofibrillary tangles, tufted astrocytes | Vertical gaze palsy, postural instability |
| Corticobasal Degeneration | CBD | Astrocytic plaques, neuronal loss | Apraxia, alien limb, asymmetric rigidity |
| Argyrophilic Grain Disease | AGD | Argyrophilic grains, coiled bodies | Limbic dysfunction, memory decline |
| Globular Glial Tauopathy | GGT | Globular glial inclusions | Frontotemporal dementia, parkinsonism |
| FTDP-17 | FTDP-17 | MAPT mutations, neuronal/ glial tau | Frontotemporal dementia, parkinsonism |
Several therapeutic strategies target common mechanisms across all 4R-tauopathies. These represent the highest-priority opportunities for disease-modifying therapies.
Tau protein dysfunction is the central pathological feature across all 4R-tauopathies. The following tau-targeted approaches are under active investigation:
| Agent | Mechanism | Disease-Specific Evidence | Clinical Status |
|---|---|---|---|
| Methylthioninium chloride (MTC) | Tau aggregation inhibitor | PSP: Phase II completed; CBD: Preclinical | PSP: Phase II completed |
| Lithium | GSK-3β inhibitor, reduces tau phosphorylation | PSP: Failed in clinical trial; CBD: Preclinical | PSP: Trial failed |
| Davunetide (AL-108) | Tau phosphorylation inhibitor | PSP: Phase II/III failed | Failed |
| Sodium phenylbutyrate | Tau acetylation modulator | ALS/FTD: Phase I/II; PSP: Under exploration | Preclinical |
Active and passive immunization approaches target pathological tau species:
The overactivation of tau kinases (GSK-3β, CDK5, JNK) promotes pathological phosphorylation. GSK-3β inhibitors have been explored extensively:
Chronic neuroinflammation drives progression across all 4R-tauopathies. Key targets include:
| Target | Approach | Status |
|---|---|---|
| CSF1R | Pexidartinib, BLZ945 for microglia depletion | Preclinical |
| TREM2 | Anti-TREM2 antibodies | Phase I/II in AD |
| CD22 | Antibody blockade | Preclinical |
Tau clearance through autophagy-lysosome and ubiquitin-proteasome pathways is impaired across 4R-tauopathies:
| Agent | Mechanism | Evidence |
|---|---|---|
| Rapamycin | mTOR inhibition | Preclinical in tauopathy models |
| Trehalose | TFEB activation, mTOR-independent autophagy | Preclinical |
| Curcumin | Autophagy induction | Preclinical |
| Urolithin A | Mitophagy enhancement | Clinical trials in AD/PD |
Several neuroprotective strategies show promise across multiple 4R-tauopathies:
PSP has the most robust therapeutic development pipeline among 4R-tauopathies:
| Target | Approach | Development Stage |
|---|---|---|
| Tau aggregation | Methylthioninium | Phase II completed |
| Tau-Specific immunotherapy | Semorinemab | Phase II failed |
| Tau kinase inhibition | Tideglusib, lithium | Failed |
| Neuroprotection | CoQ10, IGF-1 | Phase III failed |
| Oculomotor function | 3,4-Diaminopyridine | Phase II |
Key ongoing trials:
CBD therapeutic development lags behind PSP, though several approaches are emerging:
| Target | Approach | Development Stage |
|---|---|---|
| Tau immunotherapy | Semorinemab | Phase II ongoing |
| Antibody-based | Anti-tau oligomer | Preclinical |
| TREM2 modulation | Anti-TREM2 antibodies | Preclinical |
| Synaptic protection | Levetiracetam | Off-label use |
AGD lacks disease-specific clinical trials due to diagnostic challenges during life:
| Target | Approach | Development Stage |
|---|---|---|
| Tau acetylation | Salsalate, tributyrin | Preclinical |
| Anti-tau antibodies | Various | Preclinical |
| Combination therapy | Tau + neuroinflammation | Conceptual |
GGT is the rarest 4R-tauopathy with no disease-specific clinical trials. Therapeutic approaches are based on shared mechanisms:
| Target | Rationale | Development Stage |
|---|---|---|
| Oligodendrocyte protection | GOIs are hallmark | Preclinical only |
| Tau immunotherapy | Pathological tau in glia | Conceptual |
| Myelin repair | White matter involvement | Preclinical |
FTDP-17 represents a genetic 4R-tauopathy with unique therapeutic considerations:
| Target | Approach | Development Stage |
|---|---|---|
| Gene silencing | ASOs targeting MAPT | Preclinical |
| Haplotype modification | H1c risk haplotype | Conceptual |
| Tau reduction | Antisense oligonucleotides | Phase I/II planned |
| Disease | Active Trials | Failed Trials | Key Targets |
|---|---|---|---|
| PSP | 8 | 15+ | Tau, neuroprotection |
| CBD | 3 | 5+ | Tau immunotherapy |
| AGD | 0 | 0 | None |
| GGT | 0 | 0 | None |
| FTDP-17 | 0 | 0 | Genetic approaches |
| Total | 11 | 20+ |
Based on evidence strength and biological rationale, the following ranking applies across 4R-tauopathies: